Literature DB >> 15233910

Persistent and recurrent hyperparathyroidism.

Nadine R Caron1, Cord Sturgeon, Orlo H Clark.   

Abstract

More than 95% of patients with primary hyperparathyroidism (HPT) will be cured at initial operation by an experienced surgeon. Despite this success rate, persistent and recurrent HPT remain challenging clinical entities. The most cost effective and safest treatment for persistent and recurrent HPT is avoidance by successful first operation. The contributors to treatment failure can be categorized into factors related to the initial surgical procedure, anatomic variability, and the biology of disease. An understanding of the factors that commonly contribute to treatment failure can help prevent persistent and recurrent disease and plays an integral role in planning subsequent surgical approaches. Once a biochemical diagnosis of persistent or recurrent HPT is confirmed, a thorough evaluation of previous operative, pathology, and radiology reports is essential. Localization procedures supplement this information and help direct the reoperative approach. When complementary noninvasive studies, such as ultrasound, sestamibi, and magnetic resonance imaging are negative, equivocal, or discordant, invasive tests (eg, selective venous sampling for parathyroid hormone levels) are warranted. Intraoperative ultrasound and gamma-probe localization are of questionable value, but intraoperative parathyroid hormone assays help facilitate these challenging repeat dissections. Repeat parathyroid exploration is associated with more complications and fewer cures compared to the initial explorations and should only be undertaken by an experienced surgeon in a center that can provide expert preoperative localization, adjunctive intraoperative tools, and cryopreservation of parathyroid tissue when necessary. Although controversy exists regarding indications for reoperative treatment for persistent or recurrent HPT, parathyroidectomy remains the only curative treatment option. Surgery should be considered first-line treatment in most circumstances.

Entities:  

Mesh:

Year:  2004        PMID: 15233910     DOI: 10.1007/s11864-004-0024-4

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  45 in total

Review 1.  Medical approaches to primary hyperparathyroidism.

Authors:  G J Strewler
Journal:  Endocrinol Metab Clin North Am       Date:  2000-09       Impact factor: 4.741

2.  Re-operative surgery for recurrent or persistent primary hyperparathyroidism.

Authors:  C Wadström; J Zedenius; A Guinea; T S Reeve; L Delbridge
Journal:  Aust N Z J Surg       Date:  1998-02

Review 3.  Recurrent or persistent hyperparathyroidism.

Authors:  Samuel A Wells; Mary K Debenedetti; Gerard M Doherty
Journal:  J Bone Miner Res       Date:  2002-11       Impact factor: 6.741

Review 4.  Role of preoperative localization and intraoperative localization maneuvers including intraoperative PTH assay determination for patients with persistent or recurrent hyperparathyroidism.

Authors:  H Richard Alexander; Clara C Chen; Thomas Shawker; Peter Choyke; Teresa J Chan; Richard Chang; Stephen J Marx
Journal:  J Bone Miner Res       Date:  2002-11       Impact factor: 6.741

Review 5.  Percutaneous ethanol injection therapy in the treatment of thyroid and parathyroid diseases.

Authors:  F N Bennedbaek; S Karstrup; L Hegedüs
Journal:  Eur J Endocrinol       Date:  1997-03       Impact factor: 6.664

Review 6.  Reoperation for persistent or recurrent primary hyperparathyroidism.

Authors:  W Shen; M Düren; E Morita; C Higgins; Q Y Duh; A E Siperstein; O H Clark
Journal:  Arch Surg       Date:  1996-08

7.  Localization and reoperation results for persistent and recurrent parathyroid carcinoma.

Authors:  E Kebebew; C Arici; Q Y Duh; O H Clark
Journal:  Arch Surg       Date:  2001-08

8.  Reoperative parathyroid surgery in the era of sestamibi scanning and intraoperative parathyroid hormone monitoring.

Authors:  G B Thompson; C S Grant; N D Perrier; R Harman; S F Hodgson; D Ilstrup; J A van Heerden
Journal:  Arch Surg       Date:  1999-07

9.  Increased risk of death from primary hyperparathyroidism--an update.

Authors:  G Hedbäck; A Odén
Journal:  Eur J Clin Invest       Date:  1998-04       Impact factor: 4.686

Review 10.  Angiographic ablation of mediastinal parathyroid adenomas: local experience and review of the literature.

Authors:  H J Heller; G L Miller; W A Erdman; W H Snyder; N A Breslau
Journal:  Am J Med       Date:  1994-12       Impact factor: 4.965

View more
  12 in total

1.  Remedial parathyroid surgery: changing trends in 130 consecutive cases.

Authors:  Robert Udelsman; Patricia Irvin Donovan
Journal:  Ann Surg       Date:  2006-09       Impact factor: 12.969

2.  Enhancing Parathyroid Gland Visualization Using a Near Infrared Fluorescence-Based Overlay Imaging System.

Authors:  Melanie A McWade; Giju Thomas; John Q Nguyen; Melinda E Sanders; Carmen C Solórzano; Anita Mahadevan-Jansen
Journal:  J Am Coll Surg       Date:  2019-02-13       Impact factor: 6.113

3.  Differential RNA expression profile by cDNA microarray in sporadic primary hyperparathyroidism (pHPT): primary parathyroid hyperplasia versus adenoma.

Authors:  David Velázquez-Fernández; Cecilia Laurell; Milena Saqui-Salces; Juan Pablo Pantoja; Fernando Candanedo-Gonzalez; Alfredo Reza-Albarrán; Armando Gamboa-Dominguez; Miguel F Herrera
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

4.  Label-free intraoperative parathyroid localization with near-infrared autofluorescence imaging.

Authors:  Melanie A McWade; Constantine Paras; Lisa M White; John E Phay; Carmen C Solórzano; James T Broome; Anita Mahadevan-Jansen
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

5.  [Not Available].

Authors:  Annie Charbonneau
Journal:  Can J Hosp Pharm       Date:  2013-07

6.  Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT.

Authors:  Serena Grimaldi; Jacques Young; Peter Kamenicky; Dana Hartl; Marie Terroir; Sophie Leboulleux; Amandine Berdelou; Julien Hadoux; Segolene Hescot; Hervé Remy; Eric Baudin; Martin Schlumberger; Désirée Deandreis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-22       Impact factor: 9.236

7.  How long should we follow patients after apparently curative parathyroidectomy?

Authors:  Irene Lou; Courtney Balentine; Samuel Clarkson; David F Schneider; Rebecca S Sippel; Herbert Chen
Journal:  Surgery       Date:  2016-11-15       Impact factor: 3.982

8.  High success rate of parathyroid reoperation may be achieved with improved localization diagnosis.

Authors:  Ola Hessman; Peter Stålberg; Anders Sundin; Ulrike Garske; Claes Rudberg; Lars-Gunnar Eriksson; Per Hellman; Göran Akerström
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

9.  Ultrasound-guided methylene blue dye injection for parathyroid localization in the reoperative neck.

Authors:  Leah Candell; Michael J Campbell; Wen T Shen; Jessica E Gosnell; Orlo H Clark; Quan-Yang Duh
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

Review 10.  Surgical strategy for sporadic primary hyperparathyroidism an evidence-based approach to surgical strategy, patient selection, surgical access, and reoperations.

Authors:  Radu Mihai; Marcin Barczynski; Maurizio Iacobone; Antonio Sitges-Serra
Journal:  Langenbecks Arch Surg       Date:  2009-06-25       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.